Decitabine
Back to searchMolecule Structure
Scientific Name
Decitabine
Description of the Drug
Decitabine is a chemotherapeutic pyrimidine nucleoside analogue used for the treatment of myelodysplastic syndromes (MDS) by inducing DNA hypomethylation and corresponding alterations in gene expression.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB01262
http://www.drugbank.ca/drugs/DB01262
Brand Name(s)
Dacogen, Decitabine
Company Owner(s)
Cipla Ltd, Nivagen Pharmaceuticals Inc, Zydus Pharmaceuticals Usa Inc, Wockhardt Bio Ag, Novast Laboratories Ltd, Accord Healthcare Inc, Chemi Spa, Lupin Ltd, Sandoz Inc, Sagent Pharmaceuticals Inc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| DNA | NUCLEIC-ACID | INHIBITOR | CHEMBL2311221 |
| DNA (cytosine-5)-methyltransferase 1 | SINGLE PROTEIN | INHIBITOR | CHEMBL1993 |
| DNA (cytosine-5)-methyltransferase 3A | SINGLE PROTEIN | INHIBITOR | CHEMBL1992 |
Clinical Trial(s)
Unichem Links
| Atlas | 2′-deoxy-5-azacytidine | 5-aza-2′-deoxycytidine | 5-aza-2-deoxycytidine | decitabine | ||
| SureChEMBL | SCHEMBL4006 | |||||
| PharmGKB | PA164749631 | |||||
| Human Metabolome Database | HMDB0015391 | |||||
| DrugBank | DB01262 | |||||
| PubChem: Thomson Pharma | 14798099 | 14749266 | ||||
| PubChem | 451668 | |||||
| LINCS | LSM-5855 | |||||
| Nikkaji | J91.053H | |||||
| BindingDB | 96274 | |||||
| EPA CompTox Dashboard | DTXSID7030432 | |||||
| DrugCentral | 790 | |||||
| Brenda | 32104 | 139448 | 155255 | 144134 | 8386 | 72349 |
| ChemicalBook | CB6284800 | |||||
| Guide to Pharmacology | 6805 | |||||
| rxnorm | DECITABINE | DACOGEN | ||||
| PubChem: Drugs of the Future | 12013916 | |||||
| ChEBI | 50131 | |||||
| ZINC | ZINC000016929327 |
